Literature DB >> 26430078

A Novel N-Tetrasaccharide in Patients with Congenital Disorders of Glycosylation, Including Asparagine-Linked Glycosylation Protein 1, Phosphomannomutase 2, and Mannose Phosphate Isomerase Deficiencies.

Wenyue Zhang1, Philip M James2, Bobby G Ng3, Xueli Li4, Baoyun Xia1, Jiang Rong1, Ghazia Asif1, Kimiyo Raymond5, Melanie A Jones1, Madhuri Hegde1, Tongzhong Ju4, Richard D Cummings6, Katie Clarkson5, Tim Wood7, Cornelius F Boerkoel8, Hudson H Freeze3, Miao He9.   

Abstract

BACKGROUND: Primary deficiencies in mannosylation of N-glycans are seen in a majority of patients with congenital disorders of glycosylation (CDG). We report the discovery of a series of novel N-glycans in sera, plasma, and cultured skin fibroblasts from patients with CDG having deficient mannosylation.
METHOD: We used LC-MS/MS and MALDI-TOF-MS analysis to identify and quantify a novel N-linked tetrasaccharide linked to the protein core, an N-tetrasaccharide (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc) in plasma, serum glycoproteins, and a fibroblast lysate from patients with CDG caused by ALG1 [ALG1 (asparagine-linked glycosylation protein 1), chitobiosyldiphosphodolichol β-mannosyltransferase], PMM2 (phosphomannomutase 2), and MPI (mannose phosphate isomerase).
RESULTS: Glycoproteins in sera, plasma, or cell lysate from ALG1-CDG, PMM2-CDG, and MPI-CDG patients had substantially more N-tetrasaccharide than unaffected controls. We observed a >80% decline in relative concentrations of the N-tetrasaccharide in MPI-CDG plasma after mannose therapy in 1 patient and in ALG1-CDG fibroblasts in vitro supplemented with mannose.
CONCLUSIONS: This novel N-tetrasaccharide could serve as a diagnostic marker of ALG1-, PMM2-, or MPI-CDG for screening of these 3 common CDG subtypes that comprise >70% of CDG type I patients. Its quantification by LC-MS/MS may be useful for monitoring therapeutic efficacy of mannose. The discovery of these small N-glycans also indicates the presence of an alternative pathway in N-glycosylation not recognized previously, but its biological significance remains to be studied.
© 2015 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26430078      PMCID: PMC4819965          DOI: 10.1373/clinchem.2015.243279

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  12 in total

1.  Altered O-glycosylation and sulfation of airway mucins associated with cystic fibrosis.

Authors:  Baoyun Xia; James A Royall; Gautam Damera; Goverdhan P Sachdev; Richard D Cummings
Journal:  Glycobiology       Date:  2005-04-15       Impact factor: 4.313

Review 2.  Solving glycosylation disorders: fundamental approaches reveal complicated pathways.

Authors:  Hudson H Freeze; Jessica X Chong; Michael J Bamshad; Bobby G Ng
Journal:  Am J Hum Genet       Date:  2014-02-06       Impact factor: 11.025

Review 3.  Phosphomannomutase deficiency: the molecular basis of the classical Jaeken syndrome (CDGS type Ia).

Authors:  G Matthijs; E Schollen; L Heykants; S Grünewald
Journal:  Mol Genet Metab       Date:  1999-10       Impact factor: 4.797

4.  Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing.

Authors:  Sharita Timal; Alexander Hoischen; Ludwig Lehle; Maciej Adamowicz; Karin Huijben; Jolanta Sykut-Cegielska; Justyna Paprocka; Ewa Jamroz; Francjan J van Spronsen; Christian Körner; Christian Gilissen; Richard J Rodenburg; Ilse Eidhof; Lambert Van den Heuvel; Christian Thiel; Ron A Wevers; Eva Morava; Joris Veltman; Dirk J Lefeber
Journal:  Hum Mol Genet       Date:  2012-04-05       Impact factor: 6.150

5.  A sensitive green fluorescent protein biomarker of N-glycosylation site occupancy.

Authors:  Marie-Estelle Losfeld; Francesca Soncin; Bobby G Ng; Ilyas Singec; Hudson H Freeze
Journal:  FASEB J       Date:  2012-06-12       Impact factor: 5.191

6.  Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology.

Authors:  Catharina Steentoft; Sergey Y Vakhrushev; Hiren J Joshi; Yun Kong; Malene B Vester-Christensen; Katrine T-B G Schjoldager; Kirstine Lavrsen; Sally Dabelsteen; Nis B Pedersen; Lara Marcos-Silva; Ramneek Gupta; Eric Paul Bennett; Ulla Mandel; Søren Brunak; Hans H Wandall; Steven B Levery; Henrik Clausen
Journal:  EMBO J       Date:  2013-04-12       Impact factor: 11.598

7.  Glycan reductive isotope labeling for quantitative glycomics.

Authors:  Baoyun Xia; Christa L Feasley; Goverdhan P Sachdev; David F Smith; Richard D Cummings
Journal:  Anal Biochem       Date:  2009-02-10       Impact factor: 3.365

8.  Physiological changes in circulating mannose levels in normal, glucose-intolerant, and diabetic subjects.

Authors:  Hirohito Sone; Hitoshi Shimano; Hiroyuki Ebinuma; Akimitsu Takahashi; Yoshihiro Yano; Kaoruko Tada Iida; Hiroaki Suzuki; Hideo Toyoshima; Yasushi Kawakami; Yukichi Okuda; Yuichi Noguchi; Koji Ushizawa; Kazunori Saito; Nobuhiro Yamada
Journal:  Metabolism       Date:  2003-08       Impact factor: 8.694

9.  Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation.

Authors:  Baoyun Xia; Wenyue Zhang; Xueli Li; Rong Jiang; Tisa Harper; Renpeng Liu; Richard D Cummings; Miao He
Journal:  Anal Biochem       Date:  2013-08-06       Impact factor: 3.365

10.  O-GlcNAc-specific antibody CTD110.6 cross-reacts with N-GlcNAc2-modified proteins induced under glucose deprivation.

Authors:  Takahiro Isono
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

View more
  16 in total

Review 1.  What is new in CDG?

Authors:  Jaak Jaeken; Romain Péanne
Journal:  J Inherit Metab Dis       Date:  2017-05-08       Impact factor: 4.982

2.  Integrating mass spectrometry-based plasma (or serum) protein N-glycan profiling into the clinical practice?

Authors:  Arnaud Bruneel; François Fenaille
Journal:  Ann Transl Med       Date:  2019-09

3.  Increased Clinical Sensitivity and Specificity of Plasma Protein N-Glycan Profiling for Diagnosing Congenital Disorders of Glycosylation by Use of Flow Injection-Electrospray Ionization-Quadrupole Time-of-Flight Mass Spectrometry.

Authors:  Jie Chen; Xueli Li; Andrew Edmondson; Gail Ditewig Meyers; Kosuke Izumi; Amanda M Ackermann; Eva Morava; Can Ficicioglu; Michael J Bennett; Miao He
Journal:  Clin Chem       Date:  2019-02-15       Impact factor: 8.327

Review 4.  Consensus guideline for the diagnosis and management of mannose phosphate isomerase-congenital disorder of glycosylation.

Authors:  Anna Čechová; Ruqaiah Altassan; Delphine Borgel; Arnaud Bruneel; Joana Correia; Muriel Girard; Annie Harroche; Beata Kiec-Wilk; Klaus Mohnike; Tiffany Pascreau; Łukasz Pawliński; Silvia Radenkovic; Sandrine Vuillaumier-Barrot; Luis Aldamiz-Echevarria; Maria Luz Couce; Esmeralda G Martins; Dulce Quelhas; Eva Morava; Pascale de Lonlay; Peter Witters; Tomáš Honzík
Journal:  J Inherit Metab Dis       Date:  2020-04-21       Impact factor: 4.982

5.  ALG1-CDG: Clinical and Molecular Characterization of 39 Unreported Patients.

Authors:  Bobby G Ng; Sergey A Shiryaev; Daisy Rymen; Erik A Eklund; Kimiyo Raymond; Martin Kircher; Jose E Abdenur; Fusun Alehan; Alina T Midro; Michael J Bamshad; Rita Barone; Gerard T Berry; Jane E Brumbaugh; Kati J Buckingham; Katie Clarkson; F Sessions Cole; Shawn O'Connor; Gregory M Cooper; Rudy Van Coster; Laurie A Demmer; Luisa Diogo; Alexander J Fay; Can Ficicioglu; Agata Fiumara; William A Gahl; Rebecca Ganetzky; Himanshu Goel; Lyndsay A Harshman; Miao He; Jaak Jaeken; Philip M James; Daniel Katz; Liesbeth Keldermans; Maria Kibaek; Andrew J Kornberg; Katherine Lachlan; Christina Lam; Joy Yaplito-Lee; Deborah A Nickerson; Heidi L Peters; Valerie Race; Luc Régal; Jeffrey S Rush; S Lane Rutledge; Jay Shendure; Erika Souche; Susan E Sparks; Pamela Trapane; Amarilis Sanchez-Valle; Eric Vilain; Arve Vøllo; Charles J Waechter; Raymond Y Wang; Lynne A Wolfe; Derek A Wong; Tim Wood; Amy C Yang; Gert Matthijs; Hudson H Freeze
Journal:  Hum Mutat       Date:  2016-03-21       Impact factor: 4.878

Review 6.  Clinical glycomics for the diagnosis of congenital disorders of glycosylation.

Authors:  Nurulamin Abu Bakar; Dirk J Lefeber; Monique van Scherpenzeel
Journal:  J Inherit Metab Dis       Date:  2018-03-01       Impact factor: 4.982

Review 7.  CDG Therapies: From Bench to Bedside.

Authors:  Sandra Brasil; Carlota Pascoal; Rita Francisco; Dorinda Marques-da-Silva; Giuseppina Andreotti; Paula A Videira; Eva Morava; Jaak Jaeken; Vanessa Dos Reis Ferreira
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

8.  Investigation of acidic free-glycans in urine and their alteration in cancer.

Authors:  Ken Hanzawa; Miki Tanaka-Okamoto; Hiroko Murakami; Mikio Mukai; Hidenori Takahashi; Takeshi Omori; Kenji Ikezawa; Kazuyoshi Ohkawa; Masayuki Ohue; Yasuhide Miyamoto
Journal:  Glycobiology       Date:  2021-05-03       Impact factor: 4.313

9.  Bi-allelic variants in the ER quality-control mannosidase gene EDEM3 cause a congenital disorder of glycosylation.

Authors:  Daniel L Polla; Andrew C Edmondson; Sandrine Duvet; Michael E March; Ana Berta Sousa; Anna Lehman; Dmitriy Niyazov; Fleur van Dijk; Serwet Demirdas; Marjon A van Slegtenhorst; Anneke J A Kievit; Celine Schulz; Linlea Armstrong; Xin Bi; Daniel J Rader; Kosuke Izumi; Elaine H Zackai; Elisa de Franco; Paula Jorge; Sophie C Huffels; Marina Hommersom; Sian Ellard; Dirk J Lefeber; Avni Santani; Nicholas J Hand; Hans van Bokhoven; Miao He; Arjan P M de Brouwer
Journal:  Am J Hum Genet       Date:  2021-06-17       Impact factor: 11.025

10.  Offspring sex impacts DNA methylation and gene expression in placentae from women with diabetes during pregnancy.

Authors:  Jacqueline Alexander; April M Teague; Jing Chen; Christopher E Aston; Yuet-Kin Leung; Steven Chernausek; Rebecca A Simmons; Sara E Pinney
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.